CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Related Videos